Striant: profile and news






Columbia Laboratories Added to NASDAQ Biotechnology Index  May 15, 2006
...amenorrhea. The Company also markets Striant(R) (testosterone buccal system) for the treatment of hypogonadism in men. Columbia's ... - PharmaLive.com (press release),


Other information


Indication
For topical testosterone replacement therapy in males with deficiency or absence of testosterone

Pharmacology
Testosterone is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Testosterone is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Testosterone blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

Mechanism Of Action
Testosterone competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.

Drug Category
Antineoplastic Agents; Anabolic Agents; Androgens; ATC:G03BA02; ATC:G03BA03; ATC:G03EK01

Brand Names/Synonyms
AA 2500; Andriol; Andro; Andro 100; Andro L.A. 200; Androderm; Androgel; Android 10; Android 25; Android 5; Androlin; Andronaq; Andronate 100; Andronate 200; Andropatch; Andropository 200; Andrusol; Andryl 200; Beta Testosterone; CCRIS 574; CDB 111C; COL 1621; CP 601B; Cristerona T; Cristerone T; Dea No. 4000; Delatest; Delatestryl; Depo-Testosterone; Depo-Testosterone Cypionate; Depotest; Dofsol; Everone 200; Geno-Cristaux Gremy; HSDB 3398; Homosteron; Homosterone; Libigel; Malerone; Malestrone; Malogen in Oil; Malogen, Aquaspension Injection; Mertestate; Metandren; Methyltestosterone; NSC 9700; Neo-Hombreol F; Neo-Testis; Neotestis; Oreton; Oreton F; Oreton Methyl; Oreton-F; Orquisteron; Perandren; Percutacrine Androgenique; Primotest; Primoteston; Relibra; Scheinpharm Testone-Cyp; Striant; Sustanon; Sustanone; Sustason 250; Synandrol F; T-Cypionate; TES; Teslen; Testamone 100; Testandrone; Testaqua; Testex; Testiculosterone; Testim; Testobase; Testoderm; Testoderm Tts; Testogel; Testoject-50; Testolin; Testopel Pellets; Testopropon; Testosteroid; Testosteron; Testosterona [Inn-Spanish]; Testosterone; Testosterone Cypionate; Testosterone Enanthate; Testosterone Hydrate; Testosterone Propionate; Testosterone [Ban:Inn]; Testosterone and Its Esters; Testosteronum [Inn-Latin]; Testostosterone; Testoviron; Testoviron Schering; Testoviron T; Testred; Testred Cypionate 200; Testrin-P.A; Testro Aq; Testrone; Testryl; Trans-Testosterone; Virilon; Virilon Im; Virormone; Virosterone

Dosage Forms
CAPSULE; GEL; LIQUID; PATCH; SOLUTION; SUSPENSION

Absorption
Approximately 10% of the testosterone dose applied on the skin surface from AndroGel® is absorbed into systemic circulation

Interactions
-->Interactions for Testosterone:

Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.

Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, insulin requirements.

Propranolol: In a published pharmacokinetic study of an injectable testosterone product, administration of testosterone cypionate led to an increased clearance of propranolol in the majority of men tested.

Corticosteroids: The concurrent administration of testosterone with ACTH or corticosteroids may enhance edema formation; thus, these drugs should be administered cautiously, particularly in patients with cardiac or hepatic disease.

Drug/Laboratory Test Interactions

Androgens may decrease levels of thyroxin-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

 


Chemical IUPAC Name
17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one

Chemical Formula
C19H28O2

Half Life
10-100 minutes

Drug Type
Approved Drug

# Accession No
APRD00433

CAS Registry Number
58-22-0


Home | About | Cancers | Treatment | Medications
Copyright onconews.org 2005.
All Rights Reserved.
Google
 
Web onconews.org